glatiramer acetate
The heritage of glatiramer acetate and its use in multiple sclerosis
... US Glatiramer Acetate phase III study, provided clear evi- dence for the efficacy of GA, demonstrating a significant 29 % reduction favouring GA in annualised relapse rate (ARR) ...
13
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
... on glatiramer acetate administration have not revealed any worsening of spas- ticity [19, ...of glatiramer acetate on spasticity in patients with RRMS not only supported the absence of ...
9
Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
... Overall, 220 patients provided exploitable data from the MFIS questionnaire at both inclusion and study end. Measures were compared between the three-month period before inclusion and the last three months of the ...
6
Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines
... Methods: In an observational study of 203 patients treated with glatiramer acetate 20 mg subcutaneous daily, we assess the persistence and adherence in relation to the amount of care received in various ...
9
Glatiramer Acetate Treatment Increases Stability of Spinal Synapses and Down Regulates MHC I during the Course of EAE
... is glatiramer acetate (GA, Copaxone), which is an immunomodulatory drug composed of a synthetic polypeptide mixture with a 4 amino acid sequence - L-Glutamic acid, L-lysine, L-alanine and L-tyrosine ...
15
Original Article Patterns of local site reactions to subcutaneous glatiramer acetate treatment of multiple sclerosis: a clinicopathological study
... Abstract: Background: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system. Glatiramer acetate (GA) is a commonly used immunomodulating drug. It is administered ...
8
Nasal vaccination with a proteosome based adjuvant and glatiramer acetate clears β amyloid in a mouse model of Alzheimer disease
... Amyloid β-peptide (Aβ) appears to play a key pathogenic role in Alzheimer disease (AD). Immune therapy in mouse models of AD via Aβ immunization or passive administration of Aβ antibodies markedly reduces Aβ levels and ...
12
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010
... Disease-modifying therapies (DMT) in conjunction with usual symptomatic and supportive care are the primary treatments for MS. Currently available DMTs include glatiramer acetate (GA; Copaxone, Teva ...
8
Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
... The COPTIMIZE study was designed to monitor clin- ical outcomes after converting from failing or ineffective DMT therapy for RRMS to glatiramer acetate (GA) in a prospective way. GA is approved in 57 ...
9
29 gauge needles improve patient satisfaction over 27 gauge needles for daily glatiramer acetate injections
... gauge, or thinness, may be associated with an increase in bending or breakage. Thus, improving the design of the needle to reduce injection pain and site experiences without compro- mising the needle’s performance is an ...
6
Comparative effectiveness of beta interferons and glatiramer acetate for relapsing remitting multiple sclerosis : systematic review and network meta analysis of trials including recommended dosages
... First, findings from this review will require updating as generic versions of the DMTs considered here are authorised. For example, the GATE trial also tested a generic version of glatiramer acetate against ...
17
Drug adherence and multidisciplinary care in patients with multiple sclerosis: Protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study)
... Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system, for which no definitive treatment is available. Most patients start with a relapsing-remitting course ...
10
Positive and Negative Aspects of Copaxone ( Glatiramer acetate) Action on TC, TG HbA1c and Iron Levels in The Sera of Iraqi Women with Multiple Sclerosis in Baghdad Rasha Zuhair Jasim
... In the present study, (90) multiple sclerosis women in their fourth decade were enrolled , all of them have attended private clinic in Baghdad with reports of magnetic radiation image (MRI) revealing that they are ...
10
Assessing the long term effectiveness of interferon beta and glatiramer acetate in multiple sclerosis : final ten year results from the UK multiple sclerosis risk sharing scheme
... and glatiramer acetate between 2002 and 2005 and followed them up over a 10-year period in order to measure the long-term effectiveness of the drugs when compared with a modelled natural history ...
10
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial
... GA: Glatiramer acetate; iDMT: Injectable disease-modifying therapy; IFN: Interferon; IM: Intramuscular; LSM: Least-squares mean; MCS: Mental Component Summary; MRI: Magnetic resonance imaging; MS: Multiple ...
11
Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study
... Background: Glatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs for relapsing remitting multiple sclerosis (RRMS). Treatment with INFb is associated with a significant ...
7
Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients
... Background: Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been prescribed ...
9
Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)
... uPAR density (MLFI) decreased, but it was not until patients had been treated for nearly 2 years (Table 4) that these values reached statistical significance. As a group, mean values were statistically significantly ...
8
Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
... Abstract: Glatiramer acetate, a synthetic amino acid polymer analog of myelin basic protein, is one of the first approved drugs for the treatment of relapsing–remitting multiple ...of glatiramer ...
12
The potential neuroprotective effects of weekly treatment with glatiramer acetate in diabetic patients after panretinal photocoagulation
... macular edema at the first laser treatment session (week 1) and was repeated after 3 months in cases of persistent macular edema. The GA group received injections containing 20 mg of glatiramer acetate ...
7